

Press release
Lund 20 July 2020

Scandinavian ChemoTech concludes its first global conference in collaboration with the HCG Cancer Centre in India

Last week ChemoTech and HCG held their first global co-hosted conference for Tumour Specific Electroporation with participants from almost 10 countries.

As a result of the global pandemic the conference was performed through an online platform. Even though the primary target for this conference were doctors in India there were doctors from almost 10 countries in Asia, Africa and EU participating.

In addition to the general training on how to use IQwave™, doctors shared their experiences from performing the D-EECT treatment on Head & Neck- and Breast cancer patients. The doctors and scientists also discussed areas in which they would like to initiate further research using Tumour Specific Electroporation.

“We are pleased to have received such a positive response to our first project in the collaboration with HCG. This really shows a great potential for the future.” - says Mohan Frick, CEO at Scandinavian ChemoTech

“We are happy to collaborate with ChemoTech for providing electrochemotherapy services at HCG. The technology is very promising and requires further research for treating deep seated tumours and better the outcomes of current standard of care. At the HCG Translational Medicine department, we plan to conduct studies to further explore the immunomodulatory effects of chemotherapy, combinatorial approaches including potential synergism with immune check point inhibitors and radiotherapy.” – says Dr. Suhail Sayeed Mufti, Director at the Department of Translational Medicine & Therapeutics HCG

“Electrochemotherapy is a very promising technology and has shown good results in skin, head and neck and breast cancer. We are happy to collaborate with ChemoTech and provide electrochemotherapy services at all our network hospitals in India and internationally. Our translational medicine department will also look at newer indications as well as modalities to potentiate the current standard of care for solid tumours.” – says Dr. Radheshyam Naik, Head Medical Oncology, Chair, Translational Medicine and Therapeutics, Health care Global Enterprises Ltd

For more information, please contact:
Mohan Frick, Co-Founder and CEO

+46 (0)10-218 93 00
info@chemotech.se

Certified Adviser: Västra Hamnen Corporate Finance AB, Tel: +46 40 200 250,
E-mail: ca@vhcorp.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. Read more at: www.chemotech.se